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Interleukin 1 (IL-1) is a polypeptide which possesses a wide variety of biological properties.
IL-I was originally studied as "endogenous pyrogen" and "leukocytic endogenous mediator" and
more recently as "lymphocyte activating factor." Within a few minutes after intravenous
injection into experimental animals, IL-1 triggers events in the hypothalamus to initiate fever,
slow-wave sleep, and the release of a variety of neuropeptides. The nature of the IL-1 receptors
(IL-IR) is important to the understanding ofIL-i's multipleaction in mediating both neural and
non-neural events. In this paper, the data are reviewed on the physical nature of the dominant,
high-binding 80 kDa IL-IR isolated from murine T cells. In addition, newer studies demonstrate
the existence ofother IL-I binding proteins which may participate as functional IL-I receptors.
Thesearea 68-75 kDa binding protein found on Bcellsanda 26-30kDabindingproteinfoundon
T cells and mesangial cells. There is a considerable discrepancy between the number and
affinities of the 80 kDa IL-IR and biological responses. Little is known about the relationship of
the 68-75 or 26-30 kDa IL-R's biological responses. It is possible that, similar to neurotransmit-
ter receptors, multiple chainsofdifferent binding proteins participate in thesignal transduction of
IL-1. The hydrolysis of non-phosphatidyl inositol membrane phospholipids plays an important
role in responses to IL-1.
INTRODUCTION
Thediverse biological activities ofinterleukin 1 (IL-I) haveattracted interest from a
wide range of biological disciplines [1]. After systemic injection into a variety of
animals, it seems that IL-I affects nearly every organ system. Interest falls into two
groups: (1) those studying the potential beneficial effects of IL-I on host defense
mechanisms, particularly the hemopoietic stem cell, and (2) those looking at ways to
block the production and/or activity of IL-I, since many ofits biological activities are
associated with disease processes such as tissue degradation in arthritis and diabetes.
Some groups are now preparing to use IL-I in humans to bolster the stem cell's
reactivity to colony stimulating factors, while other groups are in clinical trials with
new drugs for pain and arthritis which may beeffectiveby reducing production ofIL-1.
No doubt the isolation of IL-I receptors is of vital importance to both areas of
investigation.
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CLONING OF THE 80 KDA IL-1 BINDING PROTEIN
An 80 kDa IL-I specific binding protein has been observed on a variety of cell lines
[2-7]; it recognizes both IL-la and IL-l:. Treatment of this 80 kDa protein with
glycanases reduces its size to about 65 kDa, indicating that the variation in molecular
weight sizes reported by several investigators may be due to differential glycosylation.
In addition, some experiments using tunicamycin and plant lectins suggest that the
glycosylation sites of the 80 kDa IL-I receptor may play a role in receptor affinity [8].
The 80 kDa IL-I binding protein has been purified to homogeneity from the murine
cell line E14 6.1 C10, and the 26 N-terminal amino acids have been determined [9].
Using direct in situ binding a protein has been cloned [10], and the amino acids derived
from the cDNA match the purified protein. The actual molecular weight of the 80 kDa
IL-I binding protein is 64,598 daltons. This protein, which does not match any other
protein presently reported in the various data bases, is the first IL-I receptor described.
The question remains whether this protein is the sole IL-I receptor responsible for the
multitude of biological activities of IL-1; furthermore, is there a case for the existence
of other IL-I binding proteins which, either alone or in conjuction with the 80 kDa
protein, comprise the IL-I receptor complex?
The 80 kDa IL-IR is a member of the immunoglobulin superfamily. Several groups
have been actively involved in studies on the binding of IL-I to the plasma membranes
ofvarious cells and cell lines. Ofconsiderable importance is the finding that the 80 kDa
IL-IR is a member of the immunoglobulin superfamily. The murine 80 kDa IL-iR is
composed of four sections: a 19 amino acid signal sequence, a 319 amino acid
extracellular portion, a 21 hydrophobic transmembrane segment, and a 217 amino acid
piece probably located in the cytoplasm. The sequence ofthe cytoplasmic segment does
not reveal any similarities characteristic of protein tyrosine kinases. There is a
sequence of Lys-Lys-Ser-Arg-Arg that may represent a protein kinase C phosphoryla-
tion site which could regulate receptor activity.
Similar members of the immunoglobulin superfamily, the extracellular segment of
the 80 kDa IL-iR may contain several characteristic tertiary structures of two beta
sheets connected by disulfide bonds. These structures put the 80 kDa IL-iR into the
group of receptors with other growth factors such as platelet-derived growth factor,
colony stimulating factors (CSF), and, most recently, IL-6 [I] . IL-I shares biological
activities with platelet-derived growth factor on smooth muscle cells, with CSF- 1 on
hemopoietic cells, and with IL-6 in the induction of hepatic acute-phase reactants as
well as T- and B-cell stimulation.
The extracellular segment of the 80 kDa IL-i R has three domains, with the
sequences of domains1 and 2 related; domain 3 appears less related to1 and 2. Each
domain, however, shares sequence hemology with other members of the immunoglobu-
lin superfamily. As analyzed[10], domain 1 is similar to rat CD8 chain II and domain
3 to the CB of the human T-cell receptor; domains 2 and 3 are similar to the murine
platelet-derived growth factor receptor. In the extracellular segment, seven distinct
glycosylation sites can be observed. The extent of glycosylation appears to be one
explanation ofthe various molecular weights for the IL-I binding proteins.
Since the initial molecular cloning of IL-I: [12] and IL-la [13], it has been clear
that these two proteins are, with the exception of a few stretches, not strictly
homologous molecules. The three-dimensional structure of human IL-1lf has been
reported [14], and that study shows completely beta-sheet configuration. Using
computerized molecular modeling, IL-la appears also to be a beta-sheet structure
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[Cohen F: personal communication]. Single point mutations and multiple point amino
acid addition to the N-terminal or mutations to the mid-region (histidine) results in
marked changes in the affinity of IL-1,8 for receptor binding and biological activity
[15,16]. Similar mutations in the IL-ia molecule have no effect, and it is important to
recognize the fact that the majority of receptor binding and cross-linking studies have
been reported for IL-ia (since this form survives the labeling process better than
IL-I,8). Thus, although the 80 kDa IL-IR recognizes both forms, specific binding
between the ligand and its receptor may differ for the two IL-1 forms. Site-directed
mutagenesis of the 80 kDa IL-IR will probably clarify this issue.
In human synovial cells, IL-1:fbinds with a Kd of 4 pM, whereas IL-Ia has a Kd of
66 pM [17]. Despite this 15-fold higher affinity in the binding ofIL-1l, the biological
response (induction of PGE2) was only 3.3-fold higher. Similar examples exist in the
discrepancy between the EC50 (effective concentration for half-maximal responses) for
IL-1 and its binding affinities on other cells. For example, IL-1 activates a variety of
responses on endothelial cells in the 5-50 pM range without significant specific
binding. Similar examples exist for IL-I activation offibroblasts, chondrocytes, B cells,
and neuroblastoma cells.
TWO CLASSES OF IL-IR
A second class of considerably higher affinity (1-15 pM) IL-1 receptors has been
observed by several groups [6] and appears to be distinct from the affinity (>500 pM)
of the cloned murine 80 kDa IL-IR. Several possibilities might explain the data on the
existence of two classes of IL-IR: (1) the binding of the first IL-1 molecule to the 80
kDa IL-IR changes its conformation and increases its affinity for a second IL-1
molecule [Joss U: personal communication]; (2) there are monomeric and polymeric
forms of the IL-IR [10] with increasing affinities; (3) after binding, there is a rapid
phosphorylation of non-bound receptors; and (4) another binding protein(s) exists
which forms complexes during binding, and this characteristic increases the affinity
and accounts for the two classes of binding. The MacDonald group was the first to
describe two classes of receptors on EL4 cells [3]; however, mitogen-stimulated spleen
cells apparently show both high- and low-affinity IL-1 receptors [10]. We have also
observed on several occasions two classes on EL4 and DI0.G4.1 murine T-helper cells
[18].
OTHER IL-1 BINDING PROTEINS
The possibility exists that the IL-IR has other chains, similar to the situation ofthe
IL-2R in that the p55 IL-2R subunit would be comparable to the 80 kDa binding
protein (IL-iRf3) and the 30 kDa would represent a putative second chain (IL-IRa)
which, like the p70 chain, would be a low-affinity binding protein; however, the present
80 kDa IL-iR (single subunit) has an affinity of about 500 pM, which could indicate
that a second chain has an even lower affinity; the two-chain complex would then
account for the high (5-15 pM) affinity class of receptor. A second IL-IR has been
reported from RAJI cells, a human B-cell lymphoma line, which has a Kd of 2.2 nM
for IL-I1 [16,19]. This putative second IL-IR has a molecular weight of 68 kDa; it
appears to be a distinct gene product rather than a breakdown fragment ofthe 80 kDa
IL-IR. Others have isolated monoclonal antibodies to the B-cell surface proteins and
one of these monoclonal antibodies immunoprecipitates this 68 kDa IL-iR on B-cells
[20].
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In cross-linking experiments, other IL-I specificbinding proteins have been observed
in addition to the prominent 80 kDa IL-IR. From a structural standpoint, the
"two-chain" IL-IR complex has received supporting evidence from Bird et al. [5],
Resch [21], and from our own studies [18]. The other IL-I binding proteins are 26-30
and 43-45 as well as 110 and 220 kDa. Are there other IL-I binding protein
breakdown products or aggregates? These IL-1 binding proteins are specific in that
theydo notcross-link to radiolabeled IL-I in the presenceofcompetingunlabeled IL-1.
Clearly thesmall-molecular-weight proteins which are present atapproximately 5 to
10 percent ofthe total IL-I binding the 80 kDa receptor may be breakdown products of
the 80 kDa IL-IR; however, time-dependentcross-linking experiments seem to ruleout
this possibility [21]. Furthermore, proteases are present during the cross-linking and
subsequent procedures. In addition, cell membrane preparations also reveal these
lower-molecular-weight forms which bind IL-1. As occurred in the case of the
appearance of two classes of receptors in mitogen-activated spleen cells [10], we have
been able to increase the binding (cross-linking) of radiolabeled IL-I to the 30 kDa
protein by the addition of phytohemagglutinin during the binding process at 40C
[18,22]. Mitogens may cross-link the 30 kDa protein to membrane and allow a more
efficient binding to take place. We have also produced antibodies to synthetic peptides
ofthe 80 kDa IL-IR, and these antibodies do not recognize either the 68 or the 30 kDa
protein [23]. Recently, Resch and co-workers reported the presenceofthe 30 kDa IL-I
binding protein on mesangial cells in the absence of the 80 kDa protein [Resch K:
personal communication]. Thus, we are left with the working hypothesis that these
other, smaller IL-I binding proteins are putative receptors distinct from the 80 kDa
IL-IR, which may act alone or in conjunction with the 80 kDa IL-1R.
One possible explanation for the 110 kD binding protein is a complex ofthe 80 plus
the 30 kDa binding proteins, which on SDS-PAGE, would be complexed to IL-I and
appearabout 125 kD. The 220 kD cross-linkedprotein may be adimer ofthis; however,
this possibility remains speculation at the present time. Nevertheless, these smaller-
molecular-weight IL-I binding proteins are not likely to be artifacts of cross-linking
methods since, using Jurkat cells (see below) under the same conditions, we do not
observe any significant binding, nor do we observe bands representing the 68 and 30
kDa proteins on SDS-PAGE. This result rules out many cross-linking artifacts.
SIGNAL TRANSDUCTION AND THE IL-IR
Following intravenous injection of IL-I into a variety of animals, responses such as
fever, slow-wave sleep, sodium excretion, hypotension, PGE production, and leukope-
nia occur within five to ten minutes. The vascular endothelium appears to be the likely
target for many of these and other biological effects following intravenous IL-1. In
vitro, endothelial cells respond to IL-I at 1-10 pM (orless), but IL-I specificbinding is
difficult to demonstrate or is often absent. Similarly, human neuroblastoma cells will
release arachidonic acid within seconds after exposure to fM concentrations of IL-1,
but there is no significant binding to these cells [Dransfield D, Bernheim H: personal
communication]. Thus the response of these and other cells appears to take place
without measurable association of IL-I to a plasma membrane binding receptor. How
does IL-I transduce its signal to these cells? One explanation, of course, is that very
few receptors need to be occupied for signal transduction to take place. Another
explanation is that the affinity of the small-molecular-weight receptors is too low to
allow significant cross-linking to take place.
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Recent data, however, demonstrate that IL-I may be transducing its signal via a
novel mechanism ofphospholipid hydrolysis [24]. Using Jurkat cells, IL-I will rapidly
increase the liberation ofdiacylglycerol (DAG), but this increase in DAG takes place
in the absence of hydrolysis of phosphatidylinositol 4,5-biphosphate. There is no
increase in cytosolic calcium in these cells as others have reported with other cells
following exposure to IL-1 [25]. Similarly, there is no increase in inositol triphosphate
generation; however, Jurkat cells will release phosphorylcholine fromphosphatidylcho-
line within seconds ofexposure to IL-1. The hydrolysis ofphosphatidylcholine (PC) at
very low concentrations of IL-1 (EC50 = 30 fM) reaches maximal levels at 100 fM.
The response is specific; that is, TNF has no effect and either IL-la or IL-1:3 is equally
effective. This turnover in PC has also been measured in Dl0.G4.1, EL4, and human
peripheral blood T-cells. Jurkat cells do not express detectable receptors for IL-I
(either at 40C or 370C), whereas D10.G4.1 and EL4 cells possess thousands of
receptors, and peripheral blood T cells haveonly marginal numbers ofreceptors.
These findings suggest that the presence of the 80 kDa binding protein is only
indirectly related to signal transduction. Could a putative, second very-low-affinity
chain ofthe IL-IR complex be linked to PC turnover? A similar case may be observed
in YT202 cells, which possess only the low affinity p70 IL-2R and when occupied
transduce a signal leading toNa+/H+ exchange. In such a model for the IL-iR, the 80
kDa IL-iR would bind IL-I and internalize the molecule or induce a distinct class of
signal transduction mechanisms as proposed by Mizel et al. [26]. On the other hand,
the low-affinity IL-iRa chain would not bind with a suffcient affinity for observed
binding, but would nevertheless transduce a signal via PC hydrolysis, DAG liberation,
and increased protein kinase activation.
The above model is only a working hypothesis, and the existence of other chains of
IL-iR requires evidence other than cross-linking data. Nevertheless, it does help to
explain the rapid and dramatic biological response of IL-I in vivo without significant
binding to endothelium in vitro. We have not been able to show that radiolabeled IL-I
binds to or penetrates the organum vasculosum laminae terminalis, the likely area of
IL-I/CNS interaction [Blatteis CM, DinarelloCA: unpublishedobservation] and [27].
Within a few minutes after intravenous injection, however, a variety of biological
effects are easily observed in animals. Interestingly, these are, for the most part,
associated with the rapid synthesis ofprostaglandins (particularly PGE2). The release
of14C arachidonic acid from labeled cells occurs within seconds after exposure ofIL-1,
and one source of this arachidonic acid could be DAG, which might possibly be
liberated by IL-I-induced hydrolysis ofPC. Household cyclo-oxygenase would rapidly
bring about the formation ofPGE2.
One interesting aspect ofthis model is that it separates IL-I-induced rapid increases
of PGE2 from those that require new gene expression for cyclo-oxygenase [28]. The
increase in PGE2 production by a variety of cells in vitro following IL-1 exposure
occurs toolatetoexplain therapid onsetoffever, neutropenia, orhypotension following
IL-I in vitro. Even the appearance ofIL-1-induced phospholipase A2 [29], a calcium-
activated enzyme, occurs too late to explain the release ofarachidonic acid from cells
incubated with IL-1. This finding is supported by numerous studies showing that IL-I
fails to activate intracellular calcium.
One attractive hypothesis to explain the linkage of a putative IL-iR to signal
transduction via PC turnover would be to propose that this chain is a glycosylphospho-
lipid anchored cell-surface protein [30]. These interesting cell surface proteins do not
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have an intracellular segment and are linked to membrane phosphatidylinositol via
their carboxyl terminus to ethanolamine and a carbohydrate. Recently a truncated
form of the platelet-derived growth factor receptor has been shown to be anchored to
the membrane via glycosylphosphatidylinositol linkage [31]. The THY-I alloantigen
on murine T-cells is also a glycosylphosphatidylinositol-anchored protein and plays an
important role in IL-1 effects on T cell activation [32]. It is possible that there is an
IL-IR chain which is a PC-anchored protein.
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